Recruiting

Testing a new treatment to slow memory loss in early Alzheimer's disease

Plain-English translation of NCT05462106 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This research study is testing a new medication called ACI-24.060 to see if it can help slow down or prevent memory loss in people with early-stage Alzheimer's disease and in adults with Down syndrome. The study will test different doses of the medication to find out which works best and is safest. Researchers will monitor participants for about 1 to 1.5 years to see how the treatment affects their thinking and memory.

Alzheimer's disease causes harmful proteins called amyloid to build up in the brain, leading to memory loss and cognitive decline. This trial is testing whether this medication can help prevent or slow that buildup before serious symptoms develop, potentially giving people more time with their cognitive abilities intact.

Do you qualify?

You likely qualify if…

you are between 50 and 85 years old (or 35 and 50 if you have Down syndrome) at the time you join the study
you have been diagnosed with mild cognitive impairment (early memory problems) due to Alzheimer's disease, OR you have Down syndrome with evidence of Alzheimer's-related changes
a PET scan of your brain shows evidence of amyloid buildup
you are not taking any Alzheimer's medications, or you have been on the same dose of an Alzheimer's medication for at least 2 months before joining
if you have Down syndrome, you have someone (a study partner) who spends at least 10 hours per week with you and can help answer questions about your health

You likely don't qualify if…

you have uncontrolled seizures or a history of seizures in the past 2 years
you have had a stroke or other significant brain injury
you have a serious psychiatric condition (though past depression that has been treated is usually okay)
you have a history of serious allergic reactions or immunological disorders
you have had meningitis or other serious infections of the brain or nervous system

What participation looks like

Participants will receive either the medication or a placebo (inactive treatment) at scheduled appointments over 48 to 74 weeks, depending on which group they join. You will have regular visits where your memory, thinking, and overall health are checked through tests and scans. Some participants may have PET scans or blood tests to measure how the medication affects the harmful proteins in the brain.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Testing a new treatment to slow memory loss in early Alzheimer's disease

What is this trial?

Do you qualify?

What participation looks like

Trial locations(26 sites)